Propanc Biopharma Believes PRP Reduced Toxicity Will Impact Cancer Patient Lives Significantly Jun 1, 2022
Propanc Biopharma Presents 100 Years of Clinical Evidence for “Novel” Enzyme Therapeutic Approach to Treat Cancer May 26, 2022
Propanc Biopharma Purchases Pharma Grade Raw Materials for PRP Manufacture in Preparation for Phase I First-In-Human Study May 2, 2022
Propanc Biopharma’s Management Explains Why They Believe Cancer Patients Are Likely to Respond to PRP Treatment Apr 13, 2022
Propanc Biopharma’s CEO Expresses Concern Over Disruption to Cancer Care During Global Pandemic Apr 6, 2022
Propanc Biopharma Receives Notice of Allowance for Method to Treat Cancer Stem Cells from the US Patent & Trademark Office Mar 22, 2022
Propanc Biopharma’s CEO Believes Proenzyme Therapy May Become the Healthcare Solution of Choice for Treating Cancerous Solid Tumors Mar 16, 2022
